Clinical focus and interest:
Professor Jurczak is a co-author of publications that led to the registration of ibrutinib, acalabrutinib, idelalisib, belinostat, lenalidomide, venetoclax, and rituximab biosimilars. At present, his research is focused on developing second-generation BTK inhibitors, novel monoclonal antibodies, anti-PD1 molecules, DARTs, and BiTEs. He is particularly interested in Waldenström’s macroglobulinemia, chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.
Professor Jurczak studied medicine at the Academy of Medicine, Kraków; he received his MD in 1990 and his PhD in 1996, then specialized in hematology. From 1990 to 2019, he was the chair of hematology and the leader of the lymphoma team in the Department of Hematology, Jagiellonian University Hospital. Since 2019, he has been in his current role in the Maria Skłodowska-Curie National Research Institute of Oncology. His lymphoma team took part in over 100 clinical studies, including Phase I protocols.
Professor Jurczak is a member of numerous scientific societies, including ASH, ASCO, the Polish Society of Hematology and Transfusion Medicine, the European Mantle Cell Lymphoma Network, and the International Cardio-Oncology Society. He is a consultant for the European Medicines Agency, and is a board member of the Polish Lymphoma Research Group and the chair of its clinical trial committee.